A Comprehensive Diabetes Program is more than monitoring known Diabetics
Diabetes is a leading cause of disability and death in the United States. It can result in blindness, kidney disease, nerve damage, and lowers life expectancy by 8.5 years. Roughly 84 million Americans are at risk of developing diabetes.1 Unfortunately, most glucose strip meters are only intended for monitoring known diabetics, and not cleared for use in the large population (84M) of at-risk prediabetics. Early detection is key!
HemoCue Can Help
Go to www.hemocue.us for more information or contact your local sales representative.
- The HemoCue® Glucose 201 Analyzer enables practices to test their entire at-risk patient population, not just known diabetics1. This can aid in early detection.
- Our CLIA-waived HemoCue® Glucose 201 Analyzer indication for use states the analyzer results supplement the clinical evidence in the diagnosis and treatment of patients with diabetes.
- On average reimbursement is ~48% higher than most glucose strip meters*.
* CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Any questions regarding coding should be directed to the payer being billed.
1 CDC Website: https://www.cdc.gov/diabetes/basics/quick-facts.html (Last reviewed, July 17, 2017)
Sign up for the monthly GSS Resources Newsletter, a curated eNewsletter that delivers new technology relevant to your lab type and industry straight to your inbox.